A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
Launched by EYEPOINT PHARMACEUTICALS, INC. · Nov 8, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The LUCIA trial is a study designed to test a new treatment called EYP-1901 for people with wet age-related macular degeneration (wAMD), a condition that can lead to vision loss. This trial will compare the effectiveness of EYP-1901 with an existing treatment called Aflibercept over a period of two years, with a primary focus on results after the first year.
To be eligible for the study, participants need to be adults aged 18 and older who have been diagnosed with wAMD in one eye. They should have a certain level of vision as measured on a standard eye chart. This trial is open to both individuals who have never received treatment for wAMD and those who have been treated before. Participants can expect to receive either the new treatment or the standard treatment, and they will be monitored closely throughout the study to evaluate their vision and any side effects. If you or someone you know is interested in participating, it’s a good idea to discuss it with a healthcare provider for more information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Previously treated or treatment naïve patients with a documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit.
- • Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score between 78 to 35 letters (approximately 20/32 to 20/200 Snellen equivalent) in the study eye at the Screening Visit and on Baseline (Day 1).
- • For previously-treated subjects, must have been treated with at least 2 anti-VEGF IVT injections (i.e., aflibercept 2 mg, aflibercept 8 mg, bevacizumab, ranibizumab, or faricimab) in the previous 6 months for wAMD per standard of care in the study eye prior to the Screening Visit.
- Exclusion Criteria:
- • Subfoveal fibrosis, atrophy, or scarring in the center subfield.
- • BCVA using ETDRS charts \<20 letters (20/400 Snellen equivalent) in the fellow eye.
About Eyepoint Pharmaceuticals, Inc.
Eyepoint Pharmaceuticals, Inc. is a dedicated biopharmaceutical company focused on the development and commercialization of innovative sustained-release therapies for serious eye diseases. With a strong emphasis on advancing ocular drug delivery technologies, Eyepoint aims to improve patient outcomes through its proprietary platform that enhances the efficacy and safety of therapeutic agents. The company is committed to addressing unmet medical needs in ophthalmology, leveraging its expertise to bring forward solutions that provide long-lasting benefits for patients with chronic conditions such as macular degeneration and diabetic retinopathy. Through rigorous clinical trials and a patient-centric approach, Eyepoint Pharmaceuticals strives to be at the forefront of transforming eye care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rehovot, , Israel
Austin, Texas, United States
Fort Myers, Florida, United States
Stuart, Florida, United States
Colorado Springs, Colorado, United States
Petah Tikva, , Israel
Lexington, Kentucky, United States
Arlington, Texas, United States
Nashville, Tennessee, United States
Largo, Florida, United States
Oakland, California, United States
Louisville, Kentucky, United States
Plantation, Florida, United States
San Antonio, Texas, United States
Houston, Texas, United States
Worcester, Massachusetts, United States
Encino, California, United States
Ladson, South Carolina, United States
Hagerstown, Maryland, United States
Fort Lauderdale, Florida, United States
Warrenton, Virginia, United States
Long Beach, California, United States
Edison, New Jersey, United States
West Monroe, Louisiana, United States
Mcallen, Texas, United States
Arcadia, California, United States
Saint Petersburg, Florida, United States
Oak Park, Illinois, United States
Hagerstown, Maryland, United States
Huntington Beach, California, United States
Falls Church, Virginia, United States
Deerfield Beach, Florida, United States
Metairie, Louisiana, United States
Austin, Texas, United States
Bloomfield, New Jersey, United States
Clearwater, Florida, United States
Lakewood, Colorado, United States
Glendale, California, United States
Edmond, Oklahoma, United States
Katy, Texas, United States
Bellevue, Washington, United States
Cherry Hill, New Jersey, United States
Wake Forest, North Carolina, United States
Modesto, California, United States
Amarillo, Texas, United States
Burleson, Texas, United States
Phoenix, Arizona, United States
Scottsdale, Arizona, United States
Hagerstown, Maryland, United States
Torrance, California, United States
Plano, Texas, United States
Sacramento, California, United States
Tyler, Texas, United States
Gilbert, Arizona, United States
Phoenix, Arizona, United States
Beverly Hills, California, United States
Fullerton, California, United States
Mountain View, California, United States
Oxnard, California, United States
Bloomington, Illinois, United States
Carmel, Indiana, United States
Independence, Missouri, United States
Westbury, New York, United States
Hickory, North Carolina, United States
Springfield, Oregon, United States
Beaumont, Texas, United States
San Antonio, Texas, United States
Redlands, California, United States
St. Petersburg, Florida, United States
Bethlehem, Pennsylvania, United States
Dallas, Texas, United States
Riverside, California, United States
Palm Beach Gardens, Florida, United States
New York, New York, United States
Monroeville, Pennsylvania, United States
Rapid City, South Dakota, United States
Austin, Texas, United States
East Melbourne, , Australia
Plainfield, Illinois, United States
Cary, North Carolina, United States
Portland, Oregon, United States
Albury, , Australia
Parramatta, , Australia
Sydney, , Australia
Be'er Ya'akov, , Israel
Kfar Saba, , Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported